Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada
In allogeneic hematopoietic cell transplantation (HCT), a minority of patients have access to a suitable human leukocyte antigen (HLA)-matched related donor (MRD). To fill this gap, matched unrelated donors (MUDs) are an increasingly selected donor source. Usage and outcomes after MUD HCT for Canada...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/1/10 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588729314705408 |
|---|---|
| author | Matthew D. Seftel Grace Musto David Allan Oliver Bucher Kevin Hay Ivan Pasic Tony Truong Kristjan Paulson |
| author_facet | Matthew D. Seftel Grace Musto David Allan Oliver Bucher Kevin Hay Ivan Pasic Tony Truong Kristjan Paulson |
| author_sort | Matthew D. Seftel |
| collection | DOAJ |
| description | In allogeneic hematopoietic cell transplantation (HCT), a minority of patients have access to a suitable human leukocyte antigen (HLA)-matched related donor (MRD). To fill this gap, matched unrelated donors (MUDs) are an increasingly selected donor source. Usage and outcomes after MUD HCT for Canada are not described. We investigated temporal trends in MUD compared to MRD HCT from 2000 to 2019 using data reported to the Cell Therapy and Transplant Canada (CTTC) Registry. Of 7571 first allogeneic HCTs between 2000 and 2019, the proportion of MUD HCTs rose from 35.1% to 56.3% in the early (2000–2009) and later (2010–2019) eras, respectively. Comparing the two donor sources, the 5-year overall survival (OS) after MUD HCT for patients with malignant diseases was inferior to MRD HCT in the early era (<i>p</i> < 0.001). However, in the later era, OS was comparable for the two donor sources (<i>p</i> = 0.969). For patients with non-malignant diseases, the 5-year OS after MUD HCT was inferior to MRD in the early era (<i>p</i> < 0.001), but in the later era, the 5-year OS was similar between the two donor sources (<i>p</i> = 0.209). Improvements in OS after MUD HCT were accompanied by corresponding reductions in the 2-year non-relapse mortality after MUD HCT. We conclude that MUDs are the most common donor source in Canada, and key clinical outcomes after MUD have improved over time. |
| format | Article |
| id | doaj-art-d32ea23f631647cba15b31359e2805f8 |
| institution | Kabale University |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-d32ea23f631647cba15b31359e2805f82025-01-24T13:28:20ZengMDPI AGCurrent Oncology1198-00521718-77292024-12-013211010.3390/curroncol32010010Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in CanadaMatthew D. Seftel0Grace Musto1David Allan2Oliver Bucher3Kevin Hay4Ivan Pasic5Tony Truong6Kristjan Paulson7Stem Cells, Canadian Blood Services, Ottawa, ON K1Z 7M3, CanadaDepartment of Epidemiology, CancerCare Manitoba, Winnipeg, MB R3A 1M5, CanadaStem Cells, Canadian Blood Services, Ottawa, ON K1Z 7M3, CanadaDepartment of Epidemiology, CancerCare Manitoba, Winnipeg, MB R3A 1M5, CanadaDivision of Hematology, Department of Medicine, University of Calgary, Calgary, AB T2N 1N4, CanadaHans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, CanadaDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of Calgary, Calgary, AB T3B 6A8, CanadaCancerCare Manitoba, University of Manitoba, Winnipeg, MB R3E 0V9, CanadaIn allogeneic hematopoietic cell transplantation (HCT), a minority of patients have access to a suitable human leukocyte antigen (HLA)-matched related donor (MRD). To fill this gap, matched unrelated donors (MUDs) are an increasingly selected donor source. Usage and outcomes after MUD HCT for Canada are not described. We investigated temporal trends in MUD compared to MRD HCT from 2000 to 2019 using data reported to the Cell Therapy and Transplant Canada (CTTC) Registry. Of 7571 first allogeneic HCTs between 2000 and 2019, the proportion of MUD HCTs rose from 35.1% to 56.3% in the early (2000–2009) and later (2010–2019) eras, respectively. Comparing the two donor sources, the 5-year overall survival (OS) after MUD HCT for patients with malignant diseases was inferior to MRD HCT in the early era (<i>p</i> < 0.001). However, in the later era, OS was comparable for the two donor sources (<i>p</i> = 0.969). For patients with non-malignant diseases, the 5-year OS after MUD HCT was inferior to MRD in the early era (<i>p</i> < 0.001), but in the later era, the 5-year OS was similar between the two donor sources (<i>p</i> = 0.209). Improvements in OS after MUD HCT were accompanied by corresponding reductions in the 2-year non-relapse mortality after MUD HCT. We conclude that MUDs are the most common donor source in Canada, and key clinical outcomes after MUD have improved over time.https://www.mdpi.com/1718-7729/32/1/10hematopoietic cell transplantationdonorsreal world evidence |
| spellingShingle | Matthew D. Seftel Grace Musto David Allan Oliver Bucher Kevin Hay Ivan Pasic Tony Truong Kristjan Paulson Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada Current Oncology hematopoietic cell transplantation donors real world evidence |
| title | Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada |
| title_full | Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada |
| title_fullStr | Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada |
| title_full_unstemmed | Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada |
| title_short | Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada |
| title_sort | matched unrelated donor hematopoietic cell transplantation increased usage and improvements in clinical outcomes in canada |
| topic | hematopoietic cell transplantation donors real world evidence |
| url | https://www.mdpi.com/1718-7729/32/1/10 |
| work_keys_str_mv | AT matthewdseftel matchedunrelateddonorhematopoieticcelltransplantationincreasedusageandimprovementsinclinicaloutcomesincanada AT gracemusto matchedunrelateddonorhematopoieticcelltransplantationincreasedusageandimprovementsinclinicaloutcomesincanada AT davidallan matchedunrelateddonorhematopoieticcelltransplantationincreasedusageandimprovementsinclinicaloutcomesincanada AT oliverbucher matchedunrelateddonorhematopoieticcelltransplantationincreasedusageandimprovementsinclinicaloutcomesincanada AT kevinhay matchedunrelateddonorhematopoieticcelltransplantationincreasedusageandimprovementsinclinicaloutcomesincanada AT ivanpasic matchedunrelateddonorhematopoieticcelltransplantationincreasedusageandimprovementsinclinicaloutcomesincanada AT tonytruong matchedunrelateddonorhematopoieticcelltransplantationincreasedusageandimprovementsinclinicaloutcomesincanada AT kristjanpaulson matchedunrelateddonorhematopoieticcelltransplantationincreasedusageandimprovementsinclinicaloutcomesincanada |